Clinical Trials
2 trialsNCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT04593758 2023-05-24
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Cornerstone Pharmaceuticals
Phase 1/2 Completed